Kjellström T, Blychert E, Lindgärde F
Department of Medicine, Malmö General Hospital, University of Lund, Sweden.
J Intern Med. 1991 Mar;229(3):233-9. doi: 10.1111/j.1365-2796.1991.tb00337.x.
The effect of felodipine on glucose tolerance was evaluated in 18 male type II diabetic patients treated with diet alone, who were hypertensive despite beta-blocker treatment. The study was a double-bind cross-over comparison of placebo and felodipine in addition to beta-blockade. Oral glucose tolerance tests were performed at randomization and at the end of each 4-week double-blind treatment period. The doses of felodipine given were 5 mg b.i.d. for 2 weeks followed by 10 mg b.i.d. for a further 2 weeks. Blood pressure was significantly reduced during felodipine treatment, whereas heart rate remained unaltered. HbA1c and fasting insulin levels did not change during the treatment periods. Fasting and maximal blood glucose levels were not altered between any of the treatment periods. However, there was a small but statistically significant increase (median increase 4%) in the area under the glucose concentration vs. time curve after felodipine as compared to placebo treatment. This increase was not considered to be clinically significant in the short term, but the finding merits further investigation in a rigorous long-term study.
对18名仅接受饮食治疗的男性II型糖尿病患者进行了非洛地平对糖耐量影响的评估，这些患者尽管接受了β受体阻滞剂治疗但仍患有高血压。该研究是在β受体阻滞剂治疗基础上，对安慰剂和非洛地平进行双盲交叉比较。在随机分组时以及每个4周双盲治疗期结束时进行口服葡萄糖耐量试验。给予的非洛地平剂量为5毫克，每日两次，持续2周，随后为10毫克，每日两次，再持续2周。在非洛地平治疗期间血压显著降低，而心率保持不变。治疗期间糖化血红蛋白和空腹胰岛素水平未发生变化。在任何治疗期之间，空腹和最大血糖水平均未改变。然而，与安慰剂治疗相比，非洛地平治疗后葡萄糖浓度与时间曲线下面积有小幅但具有统计学意义的增加（中位数增加4%）。短期内这种增加不被认为具有临床意义，但这一发现值得在严格的长期研究中进一步调查。
